Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX
COSMOS-Avatar: Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX
Clinical Hub for Interventional Research (CHOIR)
25 participants
Jun 6, 2025
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to develop new ways to test new drug combinations to kill tumour cells, in patients with acute myeloid leukemia (AML). The main questions it aims to answer are: * Are there new ways to speed up discovery of better treatments for AML patients using AML cells from individual from patients in special mice that can accept human tissue? * Do these mice show treatment responses that are similar to the individual AML patient from whom cells were derived? Participants with AML who are taking standard of care treatment of venetoclax and azacitidine will be asked to donate blood and bone marrow samples for this study.
Eligibility
Inclusion Criteria9
- Age 18 years and above
- Patients with suspicion of AML requiring screening procedures
- Documented diagnosis of AML by WHO Classification and/or International Consensus Classification.
- Regardless of the number and type of prior lines of therapy or eligibility for allogeneic stem cell transplantation.
- All AML subtypes are eligible.
- Concurrent participation in clinical trials is allowed.
- Documented myeloblast percentage ≥20% in the bone marrow or peripheral blood within 12 weeks of C1D1 confirmed by bone marrow aspirate or peripheral blood smear.
- Planned to commence venetoclax and azacitidine therapy.
- Provision of written informed consent prior to any study-related assessments or procedures being carried out.
Exclusion Criteria1
- \. Presence of any condition that, by assessment of the Investigator, would compromise the safety of the patient if they participated, the quality of trial data, or their adherence to the study-specified procedures.
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06782971